OS Therapies Inc — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
OS Therapies executed a placement agency agreement with Ceros Financial Services on August 6, 2026, to raise up to $10M via senior secured convertible notes in two tranches ($5M each). Investors receive 30,000 common shares and warrants to purchase 30,000 shares at $2.85/share per $100k unit. Notes convert at $2.05/share, carry 9% interest plus 7.5% OID, mature in 9 months, and are secured by company assets. Placement agent receives 5% cash fee, 5% warrant coverage, and $60k expense fee for First Tranche.
Why this rating
Financing is 20% of $49.6M market cap—meaningful but not transformational. Convertible structure and warrant dilution create pressure; company successfully exited Leonite financing. Execution risk on conversion mechanics and share reserve requirements exists.
Extracted items
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.